Amgen Mvasi, Kanjinti Sales Decline As Biosimilars Industry Faces New Policy Challenges

ASP metric used in Medicare, and often in commercial insurance, for reimbursement of physician-administered drugs is an important factor in the sales arc for biosimilars. Price negotiations under IRA could bring their own margin-squeezing pain to pharmacy-benefit biosimilars.

How A Unique Feature Of US Reimbursement Impacts Biosimilars • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics